Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. Trxade Group
  4. Financial Statements
Trxade Group logo
Trxade Group MEDS
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Trxade Group Financial Statements 2025-2011 | MEDS

Annual Financial Statements Trxade Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 		- - 5.09 M 260 K 16.5 M 41.9 M 7.28 M 3.08 M 2.16 M 2.1 M 5.22 M 8.45 M - - -

Shares

 		15.3 M 3.38 M 764 K 565 K 8.14 M 7.57 M 5.83 M 5.83 M 5.68 M 5.26 M 5.22 M 4.97 M - - -

Historical Prices

 		- - 6.66 0.46 2.03 5.53 1.25 0.528 0.38 0.4 1 1.7 - - -

Net Income

 		-41.5 M 9.07 M -17.8 M -3.47 M -5.32 M -2.54 M -284 K 9.04 K 289 K -2.76 M -1.12 M -2.01 M -2.09 M - -

Revenue

 		432 K 137 K 1.36 M 10.3 M 9.89 M 17.1 M 7.44 M 3.83 M 2.93 M 2.48 M 2.91 M 1.5 M 956 K - -

Cost of Revenue

 		100 K 131 K 1.31 M 4.73 M 5.14 M 11.4 M 2.57 M 449 K - - - - - - -

Gross Profit

 		331 K 6 K 49 K 5.52 M 4.75 M 5.71 M 4.87 M 3.38 M - 2.47 M 2.72 M 1.06 M 11.8 K - -

Operating Income

 		-42.6 M -14.7 M -4.4 M -2.92 M -5.29 M -2.51 M 125 K -87.6 K 395 K -1.01 M -137 K -1.43 M -2.08 M - -

Interest Expense

 		- - 1.2 M 336 K 23.6 K 29.4 K 53.2 K 57.5 K 157 K 152 K 120 K 4.15 K 7.28 K - -

EBITDA

 		-42.1 M -14.7 M -4.38 M -2.9 M -5.28 M -1.68 M -48.3 K 66.6 K 446 K -2.61 M -133 K -1.43 M -2.08 M - -

Operating Expenses

 		42.9 M 14.7 M 4.45 M 8.44 M 10 M 7.49 M 4.38 M 3.3 M 2.27 M 3.45 M 4.05 M 2.49 M 2.1 M - -

General and Administrative Expenses

 		7.93 M 6.68 M 1.34 M 1.69 M 1.9 M 7.49 M 4.38 M 2.35 M 2.27 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Trxade Group

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 		14.1 M 40.6 M - 19 M 14.1 M 9.43 M 8.75 M 2.37 M 1.41 M 1.04 M 905 K 771 K 681 K 10.1 M 626 K 550 K 545 K 8.18 M 8.17 M 8.16 M 8.12 M 8.09 M 8.09 M 8.06 M 7.58 M 6.97 M 6.54 M 5.75 M 5.62 M 5.56 M 5.55 M 32.1 M 32 M 32 M 32 M 32 M 32 M 31.9 M 31.7 M 31.6 M 31.5 M 31.4 M 31.4 M 31.3 M 31.3 M 31.3 M 31.3 M 29.6 M 29.4 M 29.1 M 28.8 M 27.5 M - - - - - - - - - -

Net Income

 		-3.06 M -3.4 M - -3.61 M -6.72 M -3.06 M - -3.18 M -1.83 M 21.2 M - -3.53 M -1.97 M -678 K - -503 K -1.11 M -966 K - -1.3 M -2.58 M -652 K - 138 K -543 K 180 K - 27.6 K 58 K 125 K - 94.2 K 20.5 K 82.3 K - 76.2 K -6.84 K 79.7 K - -843 K -1.1 M -372 K - -124 K -54.4 K -444 K - -352 K -301 K -922 K - -284 K -184 K - - - - - - - - -

Revenue

 		344 K 56.3 K - 590 K - 10.3 K - 64.9 K 18.7 K - - 392 K 367 K 2.25 M - 2.06 M 3.28 M 3.24 M - 2.55 M 1.9 M 3.05 M - 6.33 M 6.59 M 2.2 M - 2.31 M 1.92 M 1.51 M - 847 K 838 K 853 K - 736 K 705 K 746 K - 611 K 588 K 645 K - 1.64 M 1.17 M 696 K - 373 K 288 K 244 K - 323 K 255 K - - - - - - - - -

Cost of Revenue

 		7.86 K 2.48 K - 15.4 K - 9.58 K - 61 K 19.4 K - - 353 K 606 K 691 K - 683 K 2.11 M 1.9 M - 4 M 1.06 M 1.67 M - 4.4 M 4.59 M 563 K - 1 M 753 K 366 K - 2.34 K - - - - - - - - 770 - - - - - - - - - - - - - - - - - - - - -

Gross Profit

 		336 K 53.8 K - 575 K - 673 - 3.88 K -703 - - 39.6 K 67.1 K 1.56 M - 1.37 M 1.17 M 1.34 M - 1.28 M 841 K 1.38 M - 1.93 M 2 M 1.64 M - 1.31 M 1.16 M 1.15 M - 845 K 838 K 853 K - 736 K 705 K 746 K - 611 K 588 K 629 K - 937 K 785 K 466 K - 296 K 237 K 97.4 K - -45.3 K 132 K - - - - - - - - -

Operating Income

 		-5.16 M -3.51 M - -4.36 M -5.16 M -3.57 M - -3.5 M -1.5 M -5.49 M - -762 K -600 K -347 K - -219 K -1.1 M -969 K - -1.3 M -2.57 M -644 K - 146 K -535 K 188 K - 178 K 133 K 172 K - 91.8 K 31.4 K 98.7 K - 89.6 K 48.8 K 141 K - -245 K -578 K -130 K - -76.6 K -26.4 K -443 K - -350 K -300 K -345 K - -283 K -184 K - - - - - - - - -

Interest Expense

 		- - - - - - - - - - - 252 K 181 K 62.4 K - 130 K 9.16 K 1.36 K - 5.62 K 8.69 K 7.26 K - 7.43 K 7.31 K 7.92 K - 13.4 K 15.9 K 17.6 K - 12.6 K 10.9 K 16.5 K - 30.9 K 44.1 K 61.7 K - 50.3 K 29.8 K 40.9 K - 47.2 K 27.9 K 969 - 2.06 K 991 1.06 K - 851 563 - - - - - - - - -

EBITDA

 		-4.7 M -3.06 M - - - -3.57 M - - - -5.49 M - - - -345 K - -207 K -1.1 M -965 K - -1.29 M -2.57 M -643 K - 150 K -533 K 189 K - 182 K 135 K 173 K - 91.8 K 31.4 K 98.7 K - 89.6 K 48.8 K 141 K - -239 K -578 K -130 K - -72.8 K -24 K -441 K - -346 K -298 K -343 K - -280 K -182 K - - - - - - - - -

Operating Expenses

 		5.16 M 3.56 M - 4.94 M 5.16 M 3.57 M - 3.5 M 1.49 M 5.49 M - 801 K 667 K 1.9 M - 1.59 M 2.27 M 2.3 M - 2.58 M - 2.03 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

 		2.93 M 1.07 M - 2.17 M 2.93 M 1.36 M - 169 K 415 K 4.7 M - 66.9 K 170 K 377 K - 230 K 547 K 651 K - 917 K 2.19 M 448 K - 1.78 M 2.54 M 1.45 M - 1.13 M 1.03 M 975 K - 753 K 806 K 754 K - 646 K 656 K 604 K - 856 K 1.17 M 759 K - 1.01 M 812 K 908 K - 645 K 537 K 442 K - 238 K 316 K - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Trxade Group MEDS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Trxade Group plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Pharmaceutical retailers industry

Issuer Price % 24h Market Cap Country
Аптеки 36.6 Аптеки 36.6
APTK
 		- - - russiaRussia
LifeMD LifeMD
LFMD
 		$ 2.37 3.28 % $ 107 M usaUSA
Greenlane Holdings Greenlane Holdings
GNLN
 		$ 1.14 -6.56 % $ 8.54 M usaUSA
BOQI International Medical BOQI International Medical
BIMI
 		- 6.33 % $ 5.86 M chinaChina
Rite Aid Corporation Rite Aid Corporation
RAD
 		- - $ 35.5 M usaUSA
Walgreens Boots Alliance Walgreens Boots Alliance
WBA
 		- - $ 10.3 B usaUSA
PetMed Express PetMed Express
PETS
 		$ 1.23 -0.81 % $ 25.7 M usaUSA
China Jo-Jo Drugstores, Inc. China Jo-Jo Drugstores, Inc.
CJJD
 		- -5.59 % $ 49.9 M chinaChina
111 111
YI
 		$ 2.9 -2.68 % $ 505 M chinaChina